Rifamycin treatment to prevent TB after kidney transplant
Part of Infections clinical trials.
This study looks at whether a rifamycin-containing medicine plan is safe and effective at preventing latent (hidden) TB after a kidney transplant. If your TB test shows you likely have hidden TB, you would be offered treatment to reduce the chance it becomes active TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant
- You are able to do a blood TB test called IGRA
- If your IGRA TB test is positive, you agree to take medicine to treat latent TB
- You must be at least 20 years old
- You cannot be pregnant
- You must not have signs that suggest active (current) TB
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter, safer treatment for people with latent TB infection (TB germs in your body but not making you sick). The goal is to prevent you from getting sick with active TB later.
This trial studies whether taking rifapentine every day is safe and helps prevent active tuberculosis (TB) in people who have latent TB infection. It aims to find the best way to stop TB from becoming a serious illness later.
This study tests whether a new medicine called MK-8527, combined with the antibiotic rifampin, can safely treat latent tuberculosis infection (a dormant TB infection that shows no symptoms). You may qualify if you have untreated latent TB but feel well otherwise.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This study tests whether giving a personalized dose of rifampin (a key TB medicine) can improve treatment. It is for people with active TB that is sensitive to rifampin, and it involves frequent blood and urine tests to measure drug levels.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
Hear when a new Pulmonology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.